These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17596134)

  • 1. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
    Evans GL; Morgan RA
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.
    Chavez CL; Keravala A; Chu JN; Farruggio AP; Cuéllar VE; Voorberg J; Calos MP
    Hum Gene Ther; 2012 Apr; 23(4):390-8. PubMed ID: 22077817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tolerance to human factor VIII in mice.
    Chao H; Walsh CE
    Blood; 2001 May; 97(10):3311-2. PubMed ID: 11342466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
    Nguyen GN; Lindgren JR; Seleme MC; Kafle S; Zander CB; Zheng XL; Sabatino DE
    J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
    García-Martín C; Chuah MK; Van Damme A; Robinson KE; Vanzieleghem B; Saint-Remy JM; Gallardo D; Ofosu FA; Vandendriessche T; Hortelano G
    J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice possess a more limited natural antihuman factor VIII antibody repertoire than humans that is produced disproportionately by marginal zone B cells.
    Cormier M; Burnett E; Mo A; Notley C; Tijet N; Christie-Holmes N; Hough C; Lillicrap D
    J Thromb Haemost; 2024 Jan; 22(1):76-89. PubMed ID: 37678547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.
    Miao CH; Ye P; Thompson AR; Rawlings DJ; Ochs HD
    Blood; 2006 Jul; 108(1):19-27. PubMed ID: 16507778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.
    Chiang GG; Rubin HL; Cherington V; Wang T; Sobolewski J; McGrath CA; Gaffney A; Emami S; Sarver N; Levine PH; Greenberger JS; Hurwitz DR
    Hum Gene Ther; 1999 Jan; 10(1):61-76. PubMed ID: 10022531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.